- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Washing powder maker Nirma and Sekhmet vie for USD 731 million Glenmark Life stake: Sources
Mumbai: Indian conglomerate Nirma Ltd. and PAG-backed Sekhmet Pharmaventures are among the shortlisted bidders for a controlling stake in Glenmark Life Sciences Ltd., according to people familiar with the matter.
The suitors have entered the final round of bidding for a stake of about 83% in the Mumbai-listed company held by Glenmark Pharmaceuticals Ltd., said the people, who asked not to be identified as the information is private.
Shares of Glenmark Life rose as much as 3.8% on Friday. They were up 0.7% at 12:42 p.m. in Mumbai, valuing the controlling stake at about 60 billion rupees ($731 million).
Glenmark Pharma has been working with advisers to seek buyers for its stake in the unit as it looks to raise cash and cut debt, the people said. Deliberations are ongoing and the bidders may not proceed with formal offers, the people said. Representatives for Glenmark Life, Glenmark Pharma, Nirma and PAG declined to comment, while Sekhmet Pharmaventures didn’t respond to requests for comment.
Glenmark Life develops and manufactures active pharmaceutical ingredients in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes, its website shows. It has a portfolio of 139 molecules and supplies its products to customers in India and abroad including Europe and North America. The company has four plants in India.
Glenmark Life raised about 15 billion rupees in an initial public offering in Mumbai in July 2021. Its shares have fallen about 18% from its IPO price of 720 rupees apiece.
Nirma, known for its eponymous washing detergent brand, also makes edible salt and industrial products including soda ash and sulfuric acid, according to its website.
Sekhmet Pharmaventures is the Indian subsidiary of Gamot API, which was formed by private equity firm PAG along with Indian peers CX Partners and Samara Capital to buy stakes in fast-growing Indian pharmaceutical companies, its website shows. Sekhmet acquired a controlling stake in Anjan Drug Pvt Ltd. in 2020 and also invested in Optimus two years later.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story